Intensity Therapeutics (NASDAQ:INTS – Get Free Report) is anticipated to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Intensity Therapeutics to announce earnings of ($0.94) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.
Intensity Therapeutics (NASDAQ:INTS – Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.24). On average, analysts expect Intensity Therapeutics to post ($2.64) EPS for the current fiscal year and ($1.67) EPS for the next fiscal year.
Intensity Therapeutics Stock Down 1.5%
INTS opened at $3.38 on Wednesday. Intensity Therapeutics has a fifty-two week low of $3.00 and a fifty-two week high of $15.75. The company’s 50-day moving average is $3.71 and its 200 day moving average is $5.21. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.00 and a quick ratio of 5.00.
Analyst Ratings Changes
Several research analysts have weighed in on the company. Citigroup reissued a “buy” rating on shares of Intensity Therapeutics in a research report on Tuesday, August 11th. HC Wainwright raised their target price on Intensity Therapeutics from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Tuesday, August 18th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Intensity Therapeutics in a research note on Monday, October 19th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $7.00.
About Intensity Therapeutics
Intensity Therapeutics, Inc (NASDAQ: INTS) is a clinical-stage biotechnology company developing investigational cancer immunotherapies designed to treat solid tumors. Its approach focuses on injecting therapies directly into tumors to promote tumor-cell destruction and stimulate a broader immune response against cancer.
The company’s lead product candidate, INT230-6, is a proprietary formulation containing the chemotherapy agents cisplatin and vinblastine combined with an amphiphilic delivery agent.
Featured Stories
- Five stocks we like better than Intensity Therapeutics
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for Intensity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intensity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
